Patients with tendon, ligament, or muscle injuries that have not responded adequately to physical therapy or rest Individuals recovering from orthopedic surgery who want to support tissue healing alongside standard rehabilitation Patients with gastrointestinal conditions such as leaky gut, inflammatory bowel issues, or chronic gastric discomfort Active adults experiencing chronic joint inflammation or delayed recovery between workouts Patients already on [peptide therapy protocols](/services/peptide-therapy/) at Dr
Joint inflammation typically begins to reduce within weeks 1 to 4
TB-500 (17 aa, thymosin -4 fragment) with actin binding and cell migration
Oral Protocols: Daily oral doses of 1, 5, 10, 20, and 30 mg were evaluated over 12 weeks
ICH Q2(R2) describes validation characteristics used to interpret assay, purity, and identity results [7]